27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Epidemiological studies consistently indicate a two- to threefold increased risk of dementia among individuals with schizophrenia, although estimates vary due to diagnostic and ascertainment biases. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our study reveals that PS in DLB is associated with specific deficits in attention and visuospatial/executive function, alongside more severe neuropsychiatric symptoms. 5 key findings →
Design: longitudinal study Participants: 35 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of the 500 eligible participants (71% female, 95% non-Latino White, mean [SD] age at cohort dementia onset = 88 [7] years, mean [SD] years from onset to death = 4 [3]), only 54% received a timely diagnosis. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
After adjusting for various factors, the incidence of Alzheimer dementia was significantly higher in the anosmia group compared to the control group (hazard ratio [HR], 1.15; 95% CI, 1.04-1.28). 4 key findings →
Design: cohort study Participants: 8,023 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 18 614 ORCHARD-EPR patients (mean/SD age = 82.9/7.4 years, dementia = 20%), certain delirium (delirium = yes or ICD-10 delirium code) was present in 3077/18 614 (17%,95%CI 16%-17%) of whom 1199/3077 (39%) had dementia, and uncertain delirium (delirium = uncertain and no ICD-10 code) in 2007 (11%,10%-11%) of whom 773/2007 (39%) had dementia. 5 key findings →
Participants: 731 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Enhanced cued recall provides a simple and clinically useful memory test for identifying dementia in the elderly.
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We assessed the validity and interrater reliability of neurologists who, using four different sets of previously published criteria for the clinical diagnosis of progressive supranuclear palsy (PSP), also called Steele-Richardson-Olszewski syndrome, rated 105 autopsy-proven cases of PSP (n = 24), Lewy body disease (n = 29), corticobasal ganglionic degeneration (n = 10), postencephalitic parkinsonism (n = 7), multiple system atrophy (n = 16), Pick's disease (n = 7), and other parkinsonian or dementia disorders (n = 12). 2 key findings →
Participants: 24 Evidence: low
Full summary, score breakdown and related studies → Original source
Many older elective orthopedic surgical patients have probable cognitive impairment preoperatively. 4 key findings →
Participants: 211 Evidence: low
Full summary, score breakdown and related studies → Original source
Performance on a brief cognitive screen on admission was strongly related to subsequent change in function. 2 key findings →
Participants: 2,557 Evidence: low
Full summary, score breakdown and related studies → Original source
A 1-minute semantic fluency test can assist in early detection of dementia in the memory clinic setting. 3 key findings →
Participants: 98 Evidence: low
Full summary, score breakdown and related studies → Original source
The combination of decreased amyloid β42 (Aβ42) and increased total tau proteins (T-Tau) and phosphorylated tau (P-Tau) in cerebrospinal fluid (CSF) has recently been considered as a biological diagnostic criterion of Alzheimer's disease (AD). 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Blood-based tests have sparked tremendous attention in non-invasive early diagnosis of Alzheimer's disease (AD), a most prevalent neurodegenerative malady worldwide. 3 key findings →
Participants: 27 Evidence: low
Full summary, score breakdown and related studies → Original source
There is a pressing need to capture and track subtle cognitive change at the preclinical stage of Alzheimer's disease (AD) rapidly, cost-effectively, and with high sensitivity. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The validity of a new computerised battery called CogState was determined in 60 individuals with advanced human immunodeficiency virus-1 (HIV-1) infection from which eleven were assessed as AIDS dementia complex (ADC) stage 1 or 2. 1 key finding →
Participants: 60 Evidence: low
Full summary, score breakdown and related studies → Original source
Screening protocols in which cognitive testing is administered subsequent to patient complaint are prone to underdiagnosis. 2 key findings →
Participants: 124 Evidence: low
Full summary, score breakdown and related studies → Original source
The participants had little difficulty self-administering the CCS, which is an oft-cited barrier to computerised testing in this population. 4 key findings →
Participants: 40 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease involves a drastic departure from the cognitive, functional, and behavioural trajectory of normal ageing, and is both a dreaded and highly prevalent cause of disability to individuals, and a leading source of health and social care expenditure for society. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Many screening tools for detecting cognitive decline require in-person assessment, which is often not cost-effective or feasible for those with physical limitations. 2 key findings →
Participants: 54 Evidence: low
Full summary, score breakdown and related studies → Original source
There is no consensus for a blood-based test for the early diagnosis of Alzheimer's disease (AD). 3 key findings →
Participants: 49 Evidence: low
Full summary, score breakdown and related studies → Original source
To evaluate the utility of arterial spin-labeled blood flow magnetic resonance imaging for the detection of cerebral blood flow abnormalities in Alzheimer's disease, arterial spin-labeled blood flow images in 16 contiguous 5-mm axial sections were acquired in 18 patients diagnosed with probable Alzheimer's disease and 11 age-matched controls. 1 key finding →
Participants: 18 Evidence: low
Full summary, score breakdown and related studies → Original source
The predictive value of Aβ42 was highly affected by the type of collection tube used. 5 key findings →
Participants: 1,966 Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma biomarkers of AD using the automated Lumipulse platform show good diagnostic performance in detecting Alzheimer's pathology in cognitively unimpaired subjects. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
These results indicate that FS (p-tau231 and MMSE) has a strong potential to provide an early distinction between AD and VaD. 4 key findings →
Participants: 198 Evidence: low
Full summary, score breakdown and related studies → Original source
The p-tau181/Aβ42 ratio alone might reliably detect AD pathology in heterogeneous samples of patients suffering from different types of dementia. 1 key finding →
Participants: 526 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is the most common neurodegenerative disease in the older adults. 4 key findings →
Participants: 24 Evidence: low
Full summary, score breakdown and related studies → Original source
10 of the 1,775 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →